Why TG Therapeutics Is Tumbling 15% Today
After TG Therapeutics, Inc.'s(NASDAQ: TGTX) discussion with the FDA regarding its most advanced clinical-stage drug raised concerns over a speedy approval, shares in the company are losing 15% of their value as of 2 pm EDT.
TG Therapeutics reported earlier this year that adding its TG-1101, or ublituximab, to AbbVie Inc.'s (NYSE: ABBV) and Johnson & Johnson's (NYSE: JNJ) top-selling Imbruvica resulted in an objective response rate (ORR) of 78% in patients with high-risk chronic lymphocytic leukemia. The complete response rate to the two-drug combination was 7%. These results matched up favorably to the 45% ORR and 0% complete response rates for Imbruvica on its own.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Johnson & Johnson Stock
€225.00
-0.930%
With 57 Buy predictions and not a single Sell prediction Johnson & Johnson is an absolute favorite of our community.
As a result the target price of 228 € shows a slightly positive potential of 1.33% compared to the current price of 225.0 € for Johnson & Johnson.
